CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Peginterferon alfa-2a and Ribavirin

Last Updated: May 14, 2004
Result type: Reports
Project Number: SR0013-000
Product Line: Reimbursement Review

Generic Name: Peginterferon alfa-2a and Ribavirin

Brand Name: Pegasys RBV

Manufacturer: Hoffman-La Roche Ltd.

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 14, 2004

Recommendation Type: List in a similar manner to other drugs in class